Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00229658
Status:
COMPLETED
Last Update Posted:
2015-03-25
First Post:
2005-09-28
Brief Title:
An Observational Study Evaluating SYMLIN Pramlintide Acetate Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Prospective Open-Label Observational Study Evaluating SYMLIN Pramlintide Acetate Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing and subjects receiving SYMLIN therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None